Indian pharmaceutical company Cadila Healthcare announced the launch in the country of a generic version of the antiviral Remdesivir, an effective drug for the treatment of severe cases of COVID-19, at the most competitive price in the local market.
The medicine, which will be marketed under the brand name Remdac, will be priced at around US $ 36 (Rs 2,800) for each 100-milligram injection, the company said in a statement.
This places Remdac as the cheapest drug of this type on the market compared to generics from other Indian firms such as Cipla or Hetero, whose prices range between US $ 50 and US $ 60.
“Remdac is the most affordable drug, as we would like patients to have access to this essential drug in the treatment of COVID-19”Said Sharvil Patel, CEO of Cadila Healthcare (also known as Zydus Cadila).
This brand of Remdesivir will be available from this Thursday in public and private hospitals throughout India, the third country most affected by the pandemic and one of the main manufacturers and suppliers of medicines in the world.
India, only behind the United States and Brazil, already has 2’396,637 confirmed cases and 47,033 deaths, according to the US Johns Hopkins University.
The launch of the new generic comes after local media warned of a limited inventory of the product and the boom in its sale on the black market.
Last July, the company signed a non-exclusive agreement with the US company Gilead Sciences Inc – the main producer of the antiviral – to manufacture and sell it and, thus, increase the global supply of the drug in case of need.
The drug, whose use was authorized “of emergency”By the United States Food and Drug Administration (FDA) but not yet fully approved, it was shown to be effective in severely COVID-19 patients in clinical trials.
In order to guarantee stocks of the drug, the American Gilead said last week that, by October, it will be able to manufacture enough doses for everyone and that it is prepared to deliver two million more by the end of the year.